Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
China's drills 'incompatible' with Taiwan Strait stability: Japan FM
07/11/2025 10:00 PM - Politics
French envoy calls for stronger AI partnership with Taiwan
07/11/2025 09:46 PM - Business
Some JKoPay partners resume cooperation after brief suspension
07/11/2025 08:52 PM - Society
Bail conditions set for Core Pacific chairman in corruption trial
07/11/2025 08:28 PM - Politics
Legislature passes special act with one-off stimulus payments
07/11/2025 07:58 PM